Skip to main content

Advertisement

Figure 5 | Breast Cancer Research

Figure 5

From: VAV3 mediates resistance to breast cancer endocrine therapy

Figure 5

Association between VAV3 /VAV3 and clinical response to endocrine therapies. (A) Association between rs10494071 and the response to tamoxifen in Japanese patients. The Kaplan–Meier curves show the recurrence-free survival rate over time (years) and between patients stratified according to the three possible rs10494071 genotypes (TT, TC and CC). The logrank test P-values are shown. (B) Association between VAV3 tumor expression and response to tamoxifen (Gene Expression Omnibus data set [GSE:9195]). Graphs show the proportion of patients with metastasis-free survival over time (years) and stratified according to high (above the median) or low (below the median) VAV3 expression in breast tumors. The results shown are for three VAV3 microarray probes. Logrank P-values are shown. (C) Association between VAV3 tumor expression and the pathological response to endocrine therapies. Top panel: Graph depicting the correlation between VAV3 immunostaining score and pathological response (percentage of tumor reduction posttreatment). Bottom panels: Representative examples of the three immunostaining scores. Insets: Cells with nuclear and cytoplasmic positivity. PCC, Pearson’s correlation coefficient. (D) Examples of increased VAV3 staining at the invasive tumor front. (E) Graphs showing the Kaplan–Meier curves for patients who did or did not receive tamoxifen in the Swedish study. Panels from left to right show the results for patients whose tumors revealed low, medium or high nuclear VAV staining. The logrank test P-values are shown.

Back to article page